These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 21102634)

  • 21. Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells.
    Kettenbach AN; Schweppe DK; Faherty BK; Pechenick D; Pletnev AA; Gerber SA
    Sci Signal; 2011 Jun; 4(179):rs5. PubMed ID: 21712546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Polo-like Kinase 1 as a Target for Anti-tumor Therapy].
    Procházková I; Vojtěšek B
    Klin Onkol; 2015; 28 Suppl 2():2S32-9. PubMed ID: 26374156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aurora B kinase activation requires survivin priming phosphorylation by PLK1.
    Chu Y; Yao PY; Wang W; Wang D; Wang Z; Zhang L; Huang Y; Ke Y; Ding X; Yao X
    J Mol Cell Biol; 2011 Aug; 3(4):260-7. PubMed ID: 21148584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.
    Archambault V; Normandin K
    Cell Cycle; 2017 Jun; 16(12):1220-1224. PubMed ID: 28521657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Menendez JA
    Cell Cycle; 2011 Apr; 10(8):1295-302. PubMed ID: 21474997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selectivity-determining residues in Plk1.
    Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
    Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Playing polo during mitosis: PLK1 takes the lead.
    Combes G; Alharbi I; Braga LG; Elowe S
    Oncogene; 2017 Aug; 36(34):4819-4827. PubMed ID: 28436952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching of INCENP paralogs controls transitions in mitotic chromosomal passenger complex functions.
    Feng H; Raasholm M; Moosmann A; Campsteijn C; Thompson EM
    Cell Cycle; 2019 Sep; 18(17):2006-2025. PubMed ID: 31306061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations.
    Wu Y; Zhuo X; Dai Z; Guo X; Wang Y; Zhang C; Lai L
    Mol Biosyst; 2015 Feb; 11(2):497-505. PubMed ID: 25418836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aurora-PLK1 cascades as key signaling modules in the regulation of mitosis.
    Joukov V; De Nicolo A
    Sci Signal; 2018 Aug; 11(543):. PubMed ID: 30108183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    Schöffski P
    Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polo-like kinases inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting aurora kinases in cancer treatment.
    Kelly KR; Ecsedy J; Mahalingam D; Nawrocki ST; Padmanabhan S; Giles FJ; Carew JS
    Curr Drug Targets; 2011 Dec; 12(14):2067-78. PubMed ID: 21777198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
    Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM
    Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic depletion of Polo-like kinase 1 leads to embryonic lethality due to mitotic aberrancies.
    Wachowicz P; Fernández-Miranda G; Marugán C; Escobar B; de Cárcer G
    Bioessays; 2016 Jul; 38 Suppl 1():S96-S106. PubMed ID: 27417127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN; Louwen F; Zimmer B; Yuan J
    Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
    Wäsch R; Hasskarl J; Schnerch D; Lübbert M
    Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aurora kinases as targets for cancer therapy.
    Mountzios G; Terpos E; Dimopoulos MA
    Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells.
    Medina-Aguilar R; Marchat LA; Arechaga Ocampo E; Gariglio P; García Mena J; Villegas Sepúlveda N; Martínez Castillo M; López-Camarillo C
    Oncol Rep; 2016 Jun; 35(6):3696-704. PubMed ID: 27109433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis.
    Jiang N; Wang X; Jhanwar-Uniyal M; Darzynkiewicz Z; Dai W
    J Biol Chem; 2006 Apr; 281(15):10577-82. PubMed ID: 16478733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.